Case Study

At Laureate Pharma, Inc. we provide quality-driven solutions in order to deliver our clients’ protein therapeutic drugs successfully time after time. We have overcome unique challenges in each case and we share with you some examples of our successful projects.


cGMP Production of antibodies –
from a vial of cells to bioreactor cGMP Scale-up

Introduction

A biotechnology company with a focus on development of monoclonal antibody-based therapies for treatment of various diseases approached us to produce pre-clinical material
for toxicology studies as well as cGMP material for Phase 1 studies.

The Challenge

Our client company had a well-developed process that was ready for technology transfer. They had completed cell line development and media development and were successful in scaling up to small-scale (5L) bench-top bioreactors. However, they had no capability for large-scale production of their biotherapeutics. The client wanted Laureate to complete tech transfer and generate toxicology materials within 6 months, followed by production of Phase I materials within 9 months.

Laureate Solution

The amount of cGMP therapeutic material required for Phase I stipulated that we use a 2000L stirred tank bioreactor. We developed a successful process flow starting with a vial of Master Cell Bank cells and scaled them up in sequence in Wave 20L, 50L, 200L and 1000L bioreactors to inoculate our 2000L stirred tank bioreactor for production of product. One of our challenges in the process was to scale-up the high density and high antibody yielding CHO cells in the 1000L Wave bioreactor® to generate inoculum for the 2000L stirred tank bioreactor. To sustain the maximum viability of the cells in this large vessel, we developed optimal mixing speed by adjusting both the angle of rocking and the rock rate. Using this model we prepared the entire seed train using Wave disposable bioreactors and generated inoculum for the 2000L production reactor. The scale-up was successful and the process yielded the desired amount for phase I clinical study for our client. By using single-use technologies such as Wave bioreactor we were able to eliminate time and resource consuming clean-in-place procedures and streamline the entire manufacturing process. We completed the optimized scale up process within the time frame and the budget as stipulated by our client.

Successful Outcome:

We matched the cell growth curve done at bench scale to large-scale process and the cell growth profile closely matched that of the client’s runs. We successfully supported the high density and high titer 2000L bioreactor. We delivered Phase I clinical material within the timeline with increased productivity and efficiency and on budget.

Striving to be your #1 preferred partner in biomanufacturing.

Contact:
1-609-928-5700
[email protected]
www.laureatepharma.com

Pharmacy News

Who Regulates the Cost of Drugs and Why Can’t They Be Dispensed Free of Charge?

In social networks, you can often find calls to raise funds for medicines for a sick child. A logical question arises: why won’t the state save this child by paying for the necessary drugs? We figured out how drug prices are determined, who should regulate them, and why pharmaceutical companies do not distribute drugs to save lives. How are drug prices determined? Manufacturers of medicines and pharmacies participate in the…

Detecting Fake Medicines | Trust Pharmacy Guide for Consumers

New drugs are invented every year. Their total cost is approximately $27 million – about 1% of the entire pharmaceutical market. Thus, the risk of buying a counterfeit from a pharmacy is very small. However, there is also a factory defect or poor-quality drugs that simply will not cure a patient. MLST Trust Pharmacy has been working in the pharmaceutical market for over 10 years and has close cooperation with…

What Is A Conventional and Online Pharmacy in the USA and Canada?

Retailing pharmaceuticals in the USA is a rather huge market. Most pharmacies in the United States are private. Every person can buy absolutely any product in the US pharmacy, even if this does not apply to medications. American pharmacies occupy a fairly large area, consist of two zones – the zone for dispensing drugs and a self-service zone. In the states, almost all medications are sold only by prescription. Only…

Laureate and ARIUS Cooperation

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating…

Laureate Announces Second Manufacturing Agreement with Cytheris

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for…

Laureate Pharma Agreement with Alopexx Pharmaceuticals

Laureate To Manufacture Alopexx’s Product Candidate On April 10, 2008, Laureate Pharma, Inc., a large company engaged in biopharmaceutical development and protein production reported that it has concluded a contract manufacturing agreement with Alopexx Pharmaceuticals on the production of Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and also for fighting Staphylococcus aureus infections. The details of the agreement were not announced. “We are happy that Laureate…

Laureate Pharma Company – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma Launches New Contract Manufacturing Venture Company offers services for development and manufacture of biopharmaceuticals and sustained-release products Princeton, NJ – May 21, 2002 – Laureate Pharma Company announces the launch of contract manufacturing services at its two sites in New Jersey. Biopharmaceutical development and manufacturing services will be provided at a cGMP manufacturing facility in Princeton, NJ. Services related to sustained release microsphere products will…

Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT®

Princeton, NJ – October 25, 2006: Laureate Pharma, Inc. announced today that it has renewed its agreement with Cytogen Corporation for the cGMP manufacture of ProstaScint®, Cytogen’s proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen’s proprietary linker chelator and aseptic filling services to support Cytogen’s commercial ProstaScint® requirements. Terms of…

Laureate Pharma & DrugAbuse Sciences – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma and DrugAbuse Sciences Announce Commercial Manufacturing Services Agreement. Princeton, NJ – June 24, 2002 – Laureate Pharma L.P. and DrugAbuse Sciences, Inc. announce the initiation of a contract manufacturing agreement related to a sustained release microsphere product. Under the agreement, Laureate Pharma will provide manufacturing services for DrugAbuse Sciences’ Naltrexone Depot product, currently in clinical trials. Terms of the agreement were not disclosed. “We are…

LAUREATE PHARMA COMPLETES SALE OF TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate’s Bioprocessing Facility at Princeton, NJ to be Expanded Princeton, NJ – January 3, 2006 – Laureate Pharma, Inc., a wholly-owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE), announced today that it had completed the previously announced sale of its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash. Laureate Pharma, a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, conducts its principal operations…

Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality

– Leads implementation of Laureate’s strategic quality plan – PRINCETON, N.J., March 16, 2011 — Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Ann M. Daus, Ph.D, as Vice President, Quality. Dr. Daus will lead the implementation of Laureate’s strategic quality plan, recruit new leaders to supplement the quality management team, lead the strategic expansion of testing services and improve companywide…

Laureate Pharma Honored as Emerging Life Sciences Company of the Year

Laureate recognized for its business growth, leadership team and service innovation by the Eastern Technology Council Princeton, NJ, November 20, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has been named the “Emerging Life Science Company of the Year” by The Eastern Technology Council, the largest technology and life sciences trade association in the greater Philadelphia, PA region. The company was honored…